Clinical Trials Directory

Trials / Completed

CompletedNCT01178086

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Rituximab in the Treatment of Chronic Lymphocytic Leukemia, "CLL NIS"

Status
Completed
Phase
Study type
Observational
Enrollment
681 (actual)
Sponsor
Hoffmann-La Roche · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.

Conditions

Interventions

TypeNameDescription
DRUGRituximabRituximab IV

Timeline

Start date
2010-02-22
Primary completion
2015-06-30
Completion
2015-06-30
First posted
2010-08-09
Last updated
2018-10-05
Results posted
2018-10-05

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01178086. Inclusion in this directory is not an endorsement.

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT01178086) · Clinical Trials Directory